Beranda › Kanker Payudara › Wisconsin › Madison
Uji klinis Kanker Payudara di Madison, WI
22 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Madison (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
- UW Health Carbone Cancer Center, Madison
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Menerima pesertaFase 2
- University of Wisconsin, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Menerima pesertaFase 1
- Wisconsin Institute for Medical Research, Madison
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Menerima pesertaFase 3
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Menerima pesertaFase 3
- University of Wisconsin-Madison ( Site 0024), Madison
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Menerima pesertaFase 3
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Menerima peserta
- University of Wisconsin, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Menerima pesertaFase 1
- University of Wisconsin - Carbone Cancer Center, Madison
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Menerima pesertaFase 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Menerima pesertaFase 1/2
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Menerima pesertaFase 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Menerima pesertaFase 2
- University of Wisconsin, Madison
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Menerima pesertaFase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of 18F-FFNP Breast PET/MRI
Menerima pesertaFase 2
- UW Carbone Cancer Center, Madison
Biomarkers to Detect Endocrine Therapy Resistance
Menerima pesertaFase 2
- UW Carbone Cancer Center, Madison
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Menerima pesertaFase 2
- University of Wisconsin Carbone Cancer Center, Madison
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Menerima pesertaFase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Menerima pesertaFase 4
- University of Wisconsin, Madison
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Menerima pesertaFase 1
- UW Carbone Cancer Center, Madison
Uji klinis Kanker Payudara di kota lain
- New York City, NY134 studi
- Houston, TX126 studi
- Boston, MA111 studi
- Nashville, TN80 studi
- Los Angeles, CA72 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Durham, NC63 studi
- Queens, NY63 studi
- Chicago, IL58 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Studi lain di Madison
- Kanker Prostat29 studi
- Kanker Kolorektal22 studi
- Kanker Metastatik21 studi
- Kanker Paru Non-Sel Kecil16 studi
- Leukemia Mieloid Akut16 studi
- Melanoma15 studi
- Kanker (semua jenis)14 studi
- Kanker Ovarium13 studi
- Kanker Lambung11 studi
- Kanker Paru10 studi
- Kanker Pankreas10 studi
- Mieloma Multipel9 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.